Bioanalytical Trends: Client Needs, Platforms & Regulatory Requirements

The main discussion in Episode #101 of “The Weekly Bioanalysis” focuses on how bioanalytical testing continues to evolve alongside increasingly complex drug modalities, with our co-hosts, Dom and John, exploring the technologies, methodologies, and regulatory trends shaping modern bioanalytical laboratories. They discuss how advances in mass spectrometry, including the transition to newer SCIEX 6500 and 7500 platforms, along with emerging technologies such as the Alamar NULISA system, are enabling dramatically greater sensitivity while requiring smaller sample volumes and supporting more challenging biomarker studies. The conversation also examines the growing importance of assay selectivity, fit-for-purpose validation strategies, and the industry's ongoing debate surrounding single replicate analysis versus traditional duplicate testing as laboratories seek to balance efficiency, cost, and scientific rigor. Throughout the discussion, the hosts emphasize that no single analytical platform solves every challenge, making it increasingly important for CROs to maintain a diverse suite of technologies capable of addressing a wide range of client needs.“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.